Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases Shivakumar R; Tan W; Wilding GE; Wang ES; Wetzler MAnn Oncol 2008[Sep]; 19 (9): 1634-8BACKGROUND: Secondary acute lymphoblastic leukemia (sALL) is a rare disease and its biologic features are not well characterized. PATIENTS AND METHODS: We describe a cohort of seven patients and discuss 94 additional cases from the literature for whom biological parameters were described. Cases with incomplete data were excluded. RESULTS: Hodgkin's disease (HD) was more common in the 18-59 age group while breast and prostate cancers were prevalent only in the >or=18-year-old patients. The time interval to develop sALL was similar among all age groups but was significantly longer for HD and neuroblastoma primary diagnoses and sALL with complex karyotype. T-cell immunophenotype was more common in the <18 age group. Complete remission was infrequent in the >or=60 age group. The overall survival was poor for all sALL regardless of age, primary diagnoses, cytogenetic subgroups, or immunophenotype. Allogeneic transplantation most probably represents the only chance of cure. CONCLUSION: Better identification of prognostic factors to prevent the occurrence of sALL is indicated.|*Cause of Death[MESH]|Adolescent[MESH]|Adult[MESH]|Age Factors[MESH]|Analysis of Variance[MESH]|Antineoplastic Combined Chemotherapy Protocols/administration & dosage[MESH]|Biopsy, Needle[MESH]|Cohort Studies[MESH]|Combined Modality Therapy[MESH]|Female[MESH]|Hodgkin Disease/mortality/pathology/therapy[MESH]|Humans[MESH]|Immunohistochemistry[MESH]|Kaplan-Meier Estimate[MESH]|Leukemia, Myeloid/mortality/pathology/therapy[MESH]|Male[MESH]|Middle Aged[MESH]|Neoplasm Staging[MESH]|Neoplasms, Second Primary/*mortality/pathology/*therapy[MESH]|Precursor Cell Lymphoblastic Leukemia-Lymphoma/*mortality/pathology/*therapy[MESH]|Prognosis[MESH]|Risk Factors[MESH]|Sex Factors[MESH]|Statistics, Nonparametric[MESH]|Stem Cell Transplantation[MESH]|Survival Analysis[MESH]|Treatment Outcome[MESH] |